ALKE.NS
Latest Trade
1,948.20INRChange
81.45(+4.36%)Volume
101,998Today's Range
-
1,974.4052 Week Range
-
2,100.00As of on the National Stock Exchange of India ∙ Minimum 15 minute delay
Previous Close | 1,866.75 |
|---|---|
Open | 1,885.00 |
Volume | 101,998 |
3M AVG Volume | 0.82 |
Today's High | 1,974.40 |
Today's Low | 1,865.00 |
52 Week High | 2,100.00 |
52 Week Low | 1,660.00 |
Shares Out (MIL) | 119.57 |
Market Cap (MIL) | 232,936.50 |
Forward P/E | 23.68 |
Dividend (Yield %) | 0.82 |
India's Alkem Labs St. Louis Plant Gets FDA Form 483 With 4 Observations
India's Alkem Labs Says Got U.S. FDA Form 483 With Two Observations For Daman Unit
India's Alkem Laboratories June-Qtr Consol Net Profit Rises
Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products. The Company operates through two segments: pharmaceutical and investing. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and neutraceuticals, which it markets in India and approximately 50 countries internationally, primarily the United States. The Company offers various products, such as CLAVAM 375, CLAVAM BID DRY SYRUP, CLAVAM INJ 300MG, FREEAIR NASAL SPRAY, PAN 40MG INJECTION (VIAL), PAN/40MG TABLETS, PROWEL DRY SYRUP (30ML), TAXCLAV 100 DT TABLETS, SATROGYL O DRY SYRUP, XONE/500MG VAIL, MEROSURE KIT 500, MEROSURE 500 MG and ZADONASE, among others. The Company has approximately 16 manufacturing facilities, of which 14 manufacturing facilities are at geographically diversified locations in India and two in the United States.
Industry
Biotechnology & Drugs
Executive Leadership
Basudeo Narain Singh
Executive Chairman of the Board
Rajesh Dubey
Chief Financial Officer
Amit Ghare
President - International Business
Girish Jain
President – Research and Development
Venkatesh S.
President and Chief Executive Officer of Ascend Laboratories LLC
Price To Earnings (TTM) | 28.76 |
|---|---|
Price To Sales (TTM) | 3.09 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | 22.61 |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -- |
Return on Equity (TTM) | -- |
* U.S. FDA - APPROVAL OF NEW GENERIC OF DIOVAN WAS GRANTED TO ALKEM LABORATORIES LIMITED
India's Alkem Labs Ltd said on Wednesday the United States Food and Drug Administration (USFDA) has issued a report about its Amaliya facility, citing 13 observations following an inspection.
* GOT A FORM 483 WITH 13 OBSERVATIONS AFTER US FDA INSPECTION AT CO'S MANUFACTURING FACILITY AT AMALIYA, DAMAN
* DEC QUARTER CONSOL PROFIT 1.72 BILLION RUPEES VERSUS 2.33 BILLION RUPEES YEAR AGO
* SAYS U.S. FDA ISSUES EIR FOR CO'S MANUFACTURING FACILITY AT BADDI
* GETS SHAREHOLDERS' NOD FOR APPOINTMENT OF SANDEEP SINGH AS MD
* SEEKS SHAREHOLDERS' NOD TO RE-APPOINT DHANANJAY KUMAR SINGH AS JOINT MD Source text - http://bit.ly/2jn04KA Further company coverage:
* Sept quarter consol profit 3.27 billion rupees versus 2.88 billion rupees year ago
Alkem Laboratories Ltd * Says Prabhat Agrawal resigns as CEO Source text - http://bit.ly/2xDyT3e Further company coverage:
* sandeep Singh appointed and re-designated as managing director
* Says has received inspection report which contains two 483 observations
* June quarter consol net profit 637.8 million rupees versus profit of 2.43 billion rupees year ago
* March quarter consol profit 1.37 billion rupees versus profit 865.4 million rupees year ago
* Says US FDA has issued an establishment inspection report for its Baddi manufacturing facility
* Says us fda inspection at alkem's baddi facility Source text: http://bit.ly/2mP8JZl Further company coverage:
* Dec quarter net profit 2.14 billion rupees versus profit2.13 billion rupees year ago
* Says Alkem enters into a strategic alliance with Haw Par to exclusively market, sell and distribute Tiger Balm products in India
* Sept quarter net profit 2.95 billion rupees versus profit 2.48 billion rupees year ago
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.